Deferasirox, an iron-chelating agent, alleviates acute lung inflammation by inhibiting neutrophil activation and extracellular trap formation

Mari Kono1, Shiori Matsuhiroya1, Ayako Obuchi2, Takayuki Takahashi3, Shion Imoto4, Seiji Kawano5 and Katsuyasu Saigo2

Abstract

Objective: Reactive oxygen species (ROS) production by neutrophils induces pulmonary endothelial cell damage and results in acute lung injury (ALI). We previously reported that deferasirox (DFS), an iron-chelating agent, inhibits the ROS production and neutrophil extracellular trap (NET) formation induced by phorbol myristate acetate and formylmethionylleucylphenylalanine in vitro. In the present study, we investigated the effects of DFS in vivo using a mouse model of lipopolysaccharide (LPS)-induced ALI.

Methods: After DFS administration for 7 days, ALI was induced in mice by LPS via intratracheal administration.

Results: LPS treatment induced neutrophil invasion in the lung tissues, along with NET formation and a significant increase in the quantity of double-stranded DNA in the bronchoalveolar lavage fluid, while pre-administered DFS inhibited these phenomena. However, alteration of neutrophil morphology in the cytoplasm in terms of shape and vacuolization was not inhibited by the pre-administration of DFS, possibly through ROS production.

1Scientific Research, Scientific Affairs, Sysmex Corporation, Kobe, Japan
2Faculty of Pharmacological Sciences, Himeji Dokkyo University, Himeji, Japan
3Department of Hematology, Shinko Hospital, Kobe, Japan
4Department of Health Science, Kobe Tokiwa University, Kobe, Japan
5Integrated Clinical Education Center, Kobe University Hospital, Kobe, Japan

Corresponding author:
Mari Kono, SYSMEX Corporation, Scientific Research, Scientific Affairs, 1-3-2 Murotani, Nishiku-ku, Kobe 651-2241, Japan.
Email: Kono.Mari@sysmex.co.jp
Conclusions: DFS suppressed neutrophil invasion into lung tissues and reduced the double-stranded DNA content released by the neutrophils. These results suggest that DFS can potentially be used to prevent diseases related to neutrophil activation including ALI, thrombosis, and vascular endothelial dysfunction.

Keywords
Neutrophil, deferasirox, neutrophil extracellular traps, ALI model mouse, acute lung injury, reactive oxygen species

Date received: 19 April 2020; accepted: 28 July 2020

Introduction
Neutrophils play an important role in immune function. Activated neutrophils bind to endothelial cells and produce reactive oxygen species (ROS), resulting in injury. Redundant neutrophil activation induces various pathological conditions, including acute lung injury (ALI). The inhibitory effect of deferasirox on ROS production may help to prevent ALI development. Deferasirox (DFS, Exjade; Novartis Pharma, Basel, Switzerland), an oral iron chelator, has been reported to exert biological effects via mechanisms other than iron chelation. These mechanisms include inhibiting myeloid leukemia cell growth by suppressing the mammalian target of rapamycin signaling, disrupting the growth of solid tumors in xenograft models, preventing the nuclear translocation of nuclear factor-κB, and reducing ROS production. However, neutrophil vacuoles are formed by the fusion of endosomes with autophagosomes and secondary granules in a ROS-dependent manner. The addition of agonists such as phorbol myristate acetate or formylneuryleucylphenylalanine, we previously reported that DFS inhibits NET formation and ROS production in neutrophils, and these alterations were associated with morphological changes such as vacuolization.

Neutrophil extracellular traps (NETs) are reportedly involved in the development of ALI. NETs are webs of long chromatin fibers decorated with granule proteins that are released by neutrophils, and these webs trap and kill pathogens in the blood and tissues. They have been reported to occur in response to the generation of high levels of ROS by nicotinamide adenine dinucleotide phosphate oxidase. Neutrophils with NETs can be identified by immunostaining using antibodies against the citrullinated histones in the neutrophil nucleus. Moreover, NETs can be quantified by measuring the release of double-stranded DNA (dsDNA).

Using an in vitro system wherein neutrophils isolated from healthy donors were stimulated with phorbol myristate acetate or formylneuryleucylphenylalanine, we previously reported that DFS inhibits NET formation and ROS production in neutrophils, and these alterations were associated with morphological changes such as vacuolization. In the present study, we investigated the in vivo effect of DFS in a mouse model of ALI induced by the intratracheal administration of lipopolysaccharide (LPS).

Materials and methods
Animals
Ten-week-old, male C57BL/6J mice (Oriental Yeast, Tokyo, Japan) were
maintained in sterilized cages with a 12-hour light/dark cycle. Three mice were used per treatment group. The animals were provided with pellet chow and sterilized tap water *ad libitum*. DFS, at 20 mg/kg body weight (Ejade; Novartis, Tokyo, Japan), was intraperitoneally administered every day for 7 days. LPS at 5 mg/kg body weight was administered intratracheally, and 16 hours after LPS administration, blood, bronchoalveolar lavage fluid (BALF), and lung tissue were collected. This study was approved by the Sysmex ethics committee (approval number 2016-A-04).

**Blood collection**

Ethylendiaminetetraacetic acid (EDTA)-anticoagulated peripheral blood was collected from the heart and analyzed using an XN-2000 hematology analyzer (Sysmex, Kobe, Japan). Platelet-poor plasma samples were prepared by centrifugation at 700 \( \times g \) for 20 minutes. Neutrophil separation was performed at room temperature with the density gradient method using Mono-Poly separation medium (Dainippon-Sumitomo Pharma Biomedical, Osaka, Japan) with a purity of \( >85\% \) according to the manufacturer’s instructions.

**BALF collection**

BALF was collected from the right lung with 0.05 mM EDTA and 0.1% bovine serum albumin in phosphate-buffered saline (PBS) and analyzed using the XN-2000. Supernatant samples and precipitated cells were prepared by centrifugation at 700 \( \times g \) for 20 minutes.

**Transmission electron microscopy (TEM)**

For TEM analysis, neutrophils separated from the blood, and cells precipitated from the BALF, were fixed in 1% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) in PBS for 16 hours at 4°C. The fixed cells were then attached to silanized glass slides using Cytospin (Thermo Fisher Scientific, Rockford, IL, USA) and post-fixed in 1% osmium tetroxide for 45 minutes at 4°C. Following osmium fixation, the samples were dehydrated in a graded series of ethanol and invert-embedded in Quetol 812 (Nisshin EM, Tokyo, Japan). The samples were then cut into sections with a thickness of 80 nm to 100 nm using the Ultracut UCT ultramicrotome (Leica Microsystems, Wetzlar, Germany) and observed using an H-7500 TEM system (Hitachi High-Technologies, Tokyo, Japan).

**dsDNA measurement**

The dsDNA content in platelet-poor plasma from the blood and supernatant from the BALF was measured using an AccuBlue High Sensitivity dsDNA Quantitation Kit (31006; Biotium, Hayward, CA, USA).

**Lung tissue**

The left lung was collected, fixed with 4% paraformaldehyde in PBS, and embedded in paraffin. Paraffin sections were prepared and deparaffinized in xylene and a graded series of ethanol. The sections were subjected to hematoxylin (Mayer’s Hematoxylin Solution, 131-09665; Fujifilm Wako Pure Chemical, Osaka, Japan) and eosin (1% Eosin Y Solution, 051-06515; Fujifilm Wako Pure Chemical) staining, as well as immunohistochemical staining for citrullinated histones with an anti-histone H3 antibody at 10 mg/L (ab5103; Abcam, Cambridge, MA, USA).

**Statistical analysis**

Normal data distribution was confirmed by performing the Kolmogorov–Smirnov test and the F-test. Welch’s t-test was employed
for comparisons between two groups. EZR version 1.32 software (Jichi Medical University, Tokyo, Japan) was used for all statistical analyses. A $P$-value $<0.05$ was considered statistically significant. Data represent the mean $\pm$ standard deviation (SD). All experiments were performed in triplicate.

**Results**

**Neutrophil morphology**

Only macrophages were observed in the BALF of mice without LPS administration regardless of DFS administration (data not shown). In the LPS-administered mice, the neutrophils changed into an active shape and vacuolization in the cytoplasm was observed (Figure 1a, b). These neutrophils were noticeably different in morphology from those in the control mice, which had a stationary shape (Figure 1c). DFS administration had no significant effect on neutrophil shape.

**White blood cell (WBC) count and dsDNA content**

WBCs were counted in the BALF using an XN-2000 apparatus. LPS induced a 10-fold increase ($P < 0.01$) in the number of WBCs compared with the control, and these were almost entirely composed of neutrophils (Figure 2a). However, the WBC count in the peripheral blood was decreased (data not shown). In addition, this increase in WBC count was significantly inhibited ($P < 0.05$) in the DFS-administered mice (Figure 2a). The dsDNA content was also measured in the BALF (Figure 2b) and whole blood (Figure 2c). While LPS increased the dsDNA content in the BALF ($P < 0.05$), it did not exert an effect in the whole blood. Moreover, the increase in dsDNA content in the BALF was not

![Figure 1](image-url)

**Figure 1.** Transmission electron microscopy observation of cells in the bronchiolar lavage fluid (BALF) of acute lung injury (ALI)-induced mice. Neutrophils in the BALF of (a) ALI-induced mice treated with PBS, (b) ALI-induced mice treated with deferasirox, and (c) the control mice. Scale bars = 2 μm.
significantly inhibited in the DFS-administered mice.

**Hematoxylin and eosin staining**

The left lung was subjected to hematoxylin and eosin staining before observation. Compared with the saline-administered control mice (Figure 3a), noticeable infiltration of inflammatory cells and exudate was observed in ALI-induced mice that were intratracheally administered with LPS (Figure 3b). However, the infiltration of cells and exudate caused by LPS administration was inhibited by DFS pre-treatment (Figure 3c, d).

**Immunohistochemical staining**

Immunohistochemical staining of the lung tissue revealed that the cells were positively stained for citrullinated histones in LPS-treated mice. However, citrullinated histones were not observed before LPS administration or in the mice pretreated with DFS (Figure 4).

**Discussion**

Recent reports and reviews have shown that ALI pathogenesis is associated with neutrophil activation, which involves enhanced ROS production, NET formation, elastase release, and neutrophil accumulation in the lungs.\(^{21,22}\)

Attempts to alleviate ALI have been reported in animal studies. Glutamine inhibits ROS production by heme oxygenase-1 activation via the enhancement of glutathione synthesis, and reduced ROS generation ameliorates acute respiratory distress syndrome through the inhibition of NET formation and interferon-gamma
production. Because NETs directly damage the alveolar epithelium and endothelial cells via the production of toxic histones and myeloperoxidase, Twaddell et al. showed that NETs are effective targets in ALI treatment. In particular, ALI damage is reportedly alleviated by the depletion of neutrophils and/or platelets.

We previously reported that DFS inhibits ROS production, vacuolization, and
NET formation in vitro. However, in the present study, neutrophils that appeared in the BALF possessed vacuoles regardless of whether DFS was pre-administered. The WBC count in the BALF was significantly decreased by DFS, suggesting that the infiltration of inflammatory cells and exudate was inhibited. This was confirmed by TEM analysis. Furthermore, NET formation was partially suppressed by DFS, potentially via a decrease in both neutrophil accumulation and activation.

Although DFS did not suppress neutrophil vacuolization in our study, it did inhibit neutrophil invasion in the lung tissues. Thus far, whether DFS inhibits chemotaxis has not been demonstrated. However, it is speculated that fewer activated neutrophils and, as shown in a previous in vitro report, weakly activated neutrophils appear in the lung with DFS treatment, resulting in reduced vasculature damage. In the present study, we confirmed that DFS has the potential to prevent diseases related to neutrophil activation including ALI. Taken together, the findings of this study contribute to the prevention of ALI.

Conclusions

The WBC count in the BALF was significantly decreased by DFS, and NET formation was partially suppressed by DFS. Although DFS did not suppress neutrophil vacuolization, it did inhibit neutrophil invasion in the lung tissue. Thus, our study confirmed that DFS has the potential to prevent diseases related to neutrophil activation including ALI.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was funded by the Sysmex Corporation.

ORCID iD

Mari Kono https://orcid.org/0000-0002-7646-9118

References

1. Ghoti H, Fibach E, Merkel D, et al. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 2010; 95: 1433–1434.
2. Lui GY, Obeidy P, Ford SJ, et al. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol 2013; 83: 179–190.
3. Shaz BH, Stowell SR and Hillyer CD. Transfusion-related acute lung injury: from bedside to bench and back. Blood 2011; 117: 1463–1471.
4. Banerjee A, Mifsud NA, Bird R, et al. The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia. Br J Haematol 2015; 168: 576–582.
5. Ohyashiki JH, Kobayashi C, Hamamura R, et al. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009; 100: 970–977.
6. Messa E, Carturan S, Maffe C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010; 95: 1308–1316.
7. Saigo K, Kono M, Takagi Y, et al. Deferasirox reduces oxidative stress in
patients with transfusion dependency. *J Clin Med Res* 2013; 5: 57–60.

8. Kono M, Saigo K, Takagi Y, et al. Morphological and flow-cytometric analysis of haemin-induced human neutrophil activation: implications for transfusion-related acute lung injury. *Blood Transfus* 2013; 11: 53–60.

9. Mihalache CC, Yousefi S, Conus S, et al. Inflammation-associated autophagy-related programmed necrotic death of human neutrophils characterized by organelle fusion events. *J Immunol* 2011; 186: 6532–6542.

10. Karlsson A, Nixon JB and McPhail LC. Phorbol myristate acetate induces neutrophil NADPH-oxidase activity by two separate signal transduction pathways: dependent or independent of phosphatidylinositol 3-kinase. *J Leukoc Biol* 2000; 67: 396–404.

11. Mitroulis I, Kourtzelis I, Kambas K, et al. Regulation of the autophagic machinery in human neutrophils. *Eur J Immunol* 2010; 40: 1461–1472.

12. Thomas GM, Carbo C, Curtis BR, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. *Blood* 2012; 119: 6335–6343.

13. Kono M, Saigo K, Yamamoto S, et al. Iron-chelating agent, deferasirox, inhibits neutrophil activation and extracellular trap formation. *Clin Exp Pharmacol Physiol* 2016; 43: 915–920.

14. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. *Science* 2004; 303: 1532–1535.

15. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. *J Cell Biol* 2007; 176: 231–241.

16. Hirose T, Hamaguchi S, Matsumoto N, et al. Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream of critically ill patients. *PLoS One* 2014; 9: e111755.

17. Arai Y, Yamashita K, Mizugishi K, et al. Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation. *Biol Blood Marrow Transplant* 2013; 19: 1683–1689.

18. Kono M, Saigo K, Matsuhiroya S, et al. Detection of activated neutrophils by reactive oxygen species production using a hematology analyzer. *J Immunol Methods* 2018; 463: 122–126.

19. Ritter C, Da Cunha AA, Echer IC, et al. Effects of N-acetylcysteine plus deferoxamine in lipopolysaccharide-induced acute lung injury in the rat. *Crit Care Med* 2006; 34: 471–477.

20. Grommes J, Mörgelin M and Soehnlein O. Pioglitazone attenuates endotoxin-induced acute lung injury by reducing neutrophil recruitment. *Eur Respir J* 2012; 40: 416–423.

21. Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. *J Clin Invest* 2012; 122: 2661–2671.

22. Rebetz J, Semple JW and Kapur R. The pathogenic involvement of neutrophils in acute respiratory distress syndrome and transfusion-related acute lung injury. *Transfus Med Hemother* 2018; 45: 290–298.

23. De Oliveira GP, Kitoko JZ, De Souza Lima-Gomes P, et al. Glutamine therapy reduces inflammation and extracellular trap release in experimental acute respiratory distress syndrome of pulmonary origin. *Nutrients* 2019; 11: 831.

24. Saffarzadeh M, Juenemann C, Queisser MA, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. *PLoS One* 2012; 7: e32366.

25. Twaddell SH, Baines KJ, Grainge C, et al. The emerging role of neutrophil extracellular traps in respiratory disease. *Chest* 2019; 156: 774–782.